{"prompt": "['Dosing Modification and Toxicity Management Guidelines for Immune-Mediated, Infusion-Related, and', 'Non-Immune-Mediated Reactions (MEDI4736 Monotherapy or Combination Therapy With Tremelimumab or Tremelimumab', 'Monotherapy) 1 November 2017 Version', 'General Considerations', 'Dose Modifications', 'Toxicity Management', 'permanently discontinued in Grade 2 events with high likelihood for morbidity and/or mortality - e.g.,', 'myocarditis, or other similar events even if they are not currently noted in the guidelines - when they do', 'not rapidly improve to Grade <1 upon treatment with systemic steroids and following full taper', 'Note: There are some exceptions to permanent discontinuation of study drug for Grade 4 events (i.e.,', 'hyperthyroidism, hypothyroidism, Type 1 diabetes mellitus).', 'AE Adverse event; CTC Common Toxicity Criteria; CTCAE Common Terminology Criteria for Adverse Events; imAE immune-mediated adverse event; IV intravenous; NCI National Cancer Institute; PO By mouth.', 'Pediatric Considerations', 'Dose Modifications', 'Toxicity Management', 'The criteria for permanent discontinuation of study drug/study regimen based on CTC grade/severity is', '-', 'All recommendations for specialist consultation should occur with a pediatric', 'the same for pediatric patients as it is for adult patients, as well as to permanently discontinue study', 'specialist in the specialty recommended.', '-', 'drug/study regimen if unable to reduce corticosteroid < a dose equivalent to that required for', 'The recommendations for dosing of steroids (i.e., mg/kg/day) and for IV IG and', 'plasmapheresis that are provided for adult patients should also be used for pediatric', 'corticosteroid replacement therapy within 12 weeks after last dose of study drug/study regimen', 'patients.', '-', 'The infliximab 5 mg/kg IV dose recommended for adults is the same as recommended', 'for pediatric patients 6 years old. For dosing in children younger than 6 years old,', 'consult with a pediatric specialist.', '-', 'For pediatric dosing of mycophenolate mofetil, consult with a pediatric specialist.', '-', 'With long-term steroid and other immunosuppressive use, consider need for PJP', 'prophylaxis, gastrointestinal protection, and glucose monitoring.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 91 de 123']['Specific Immune-Mediated Reactions', 'Adverse Events', 'Severity Grade of the', 'Dose Modifications', 'Toxicity Management', 'Event (NCI CTCAE', 'version 4.03)', 'Pneumonitis/Interstitia Lung Disease', 'Any Grade', 'General Guidance', 'For Any Grade:', '(ILD)', '-', 'Monitor patients for signs and symptoms of pneumonitis or ILD (new', 'onset or worsening shortness of breath or cough). Patients should be', 'evaluated with imaging and pulmonary function tests, including other', 'diagnostic procedures as described below.', '-', 'Initial work-up may include clinical evaluation, monitoring of', 'oxygenation via pulse oximetry (resting and exertion), laboratory work-', 'up, and high-resolution CT scan.', 'Grade 1', 'No dose modifications required. However,', 'For Grade 1 (radiographic changes only):', '(asymptomatic, clinical', 'consider holding study drug/study', '-', 'Monitor and closely follow up in 2 to 4 days for clinical symptoms,', 'regimen dose as clinically appropriate and', 'pulse oximetry (resting and exertion), and laboratory work-up and then', 'or diagnostic', 'as clinically indicated.', 'observations only;', 'during diagnostic work-up for other', '-', 'Consider Pulmonary and Infectious disease consult.', 'intervention not', 'etiologies.', 'indicated)', 'Grade 2', 'Hold study drug/study regimen dose until', 'For Grade 2 (mild to moderate new symptoms):', 'Grade 2 resolution to Grade <1.', '-', '(symptomatic; medical', 'Monitor symptoms daily and consider hospitalization.', 'If toxicity worsens, then treat as', '-', 'intervention indicated;', 'Promptly start systemic steroids (e.g., prednisone 1 to 2 mg/kg/day PO', 'Grade 3 or Grade 4.', 'or IV equivalent).', 'limiting instrumental', 'If toxicity improves to Grade 1,', '-', 'Reimage as clinically indicated.', 'ADL)', 'then the decision to reinitiate study', '-', 'If no improvement within 3 to 5 days, additional workup should be', 'drug/study regimen will be based', 'considered and prompt treatment with IV methylprednisolone 2 to', \"upon treating physician's clinical\", '4 mg/kg/day started', 'judgment and after completion of', '-', 'If still no improvement within 3 to 5 days despite IV', 'steroid taper.', 'methylprednisolone at 2 to 4 mg/kg/day, promptly start', 'immunosuppressive therapy such as TNF inhibitors (e.g., infliximab at', '5 mg/kg every 2 weeks). Caution: It is important to rule out sepsis and', 'refer to infliximab label for general guidance before using infliximab.', '-', 'Once the patient is improving, gradually taper steroids over >28 days', 'and consider prophylactic antibiotics, antifungals, or anti-PJP treatment', '(refer to current NCCN guidelines for treatment of cancer-related', 'infections [Category 2B recommendation])', '-', 'Consider pulmonary and infectious disease consult.', '-', 'Consider, as necessary, discussing with study physician.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 92 de 123']\n\n###\n\n", "completion": "END"}